Established biomarkers such as blood eosinophil count (BEC), FeNO, and serum IgE levels are pivotal in guiding biologic selection, particularly for T2 inflammation-targeted therapies, optimizing treatment efficacy in conditions like asthma and atopic dermatitis (AD). The gene discussed is IGHE; the disease is atopic eczema.